新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.
作者信息
Sabnis Ram W, Sabnis Anika R
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
出版信息
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
Abstract
Provided herein are novel pyridine derivatives as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychiatric disorders, and processes for preparing such compounds.
摘要
本文提供了作为5-HT2A激动剂的新型吡啶衍生物、药物组合物、此类化合物在治疗精神疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
2
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
3
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
4
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
5
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
6
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.
ACS Med Chem Lett. 2025 May 9;16(6):933-934. doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.
7
Novel Azaindazole Derivatives as HCN2 Modulators for Treating Central Nervous System and Psychiatric Disorders, Namely, Schizophrenia, Autism, and Mood Disorders.
ACS Med Chem Lett. 2025 May 9;16(6):927-928. doi: 10.1021/acsmedchemlett.5c00228. eCollection 2025 Jun 12.
8
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
9
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.
ACS Med Chem Lett. 2024 Dec 10;16(1):12-13. doi: 10.1021/acsmedchemlett.4c00573. eCollection 2025 Jan 9.
10
Novel Desamide Isotryptamine Tetracycles as 5‑HT2C Agonists for Treating Brain Disorders.
ACS Med Chem Lett. 2025 May 21;16(6):976-977. doi: 10.1021/acsmedchemlett.5c00286. eCollection 2025 Jun 12.
引用本文的文献
1
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
2
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
3
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
本文引用的文献
1
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
2
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
3
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.
ACS Pharmacol Transl Sci. 2024 May 8;7(6):1722-1745. doi: 10.1021/acsptsci.4c00157. eCollection 2024 Jun 14.
4
Psychedelic therapy in depression and substance use disorders.
Eur J Neurosci. 2024 Jul;60(2):4063-4077. doi: 10.1111/ejn.16421. Epub 2024 May 21.
5
The role of serotonin in depression-A historical roundup and future directions.
J Neurochem. 2024 Sep;168(9):1751-1779. doi: 10.1111/jnc.16097. Epub 2024 Mar 13.
6
Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.
Chem Rev. 2024 Jan 10;124(1):124-163. doi: 10.1021/acs.chemrev.3c00375. Epub 2023 Nov 30.
Zotero 插件